Cookson Peirce & Co. Inc. Takes $558,000 Position in Nurix Therapeutics, Inc. $NRIX

Cookson Peirce & Co. Inc. bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,000 shares of the company’s stock, valued at approximately $558,000.

Several other large investors have also recently made changes to their positions in NRIX. Larson Financial Group LLC lifted its position in Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Nurix Therapeutics in the 4th quarter worth $33,000. KBC Group NV purchased a new position in Nurix Therapeutics during the 1st quarter worth $34,000. Finally, Wexford Capital LP acquired a new position in Nurix Therapeutics during the 3rd quarter valued at about $41,000.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of Nurix Therapeutics stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at $2,930,675. The trade was a 3.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,314 shares of company stock worth $589,361 over the last ninety days. 6.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NRIX shares. UBS Group lifted their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Morgan Stanley raised their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Jefferies Financial Group boosted their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Royal Bank Of Canada upped their target price on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Finally, Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.21.

Nurix Therapeutics Stock Performance

NRIX opened at $26.21 on Monday. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $28.23. The firm has a 50 day moving average of $24.37 and a two-hundred day moving average of $19.01. The firm has a market capitalization of $2.72 billion, a PE ratio of -7.60 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The business had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. As a group, analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.